A drug developed to fight cancer is showing early promise as a treatment for pulmonary hypertension. In the first human trial of sorafenib as a treatment for pulmonary hypertension, 8 out of the first 9 patients increased their ability to exercise. Six out of 9 had improved right ventricular ejection fraction. Four had a significant decrease in pulmonary artery pressures.